AI Article Synopsis
- Solar urticaria is a challenging form of allergy triggered by sunlight, and common treatments often don't work for some patients, negatively impacting their daily lives.
- A case study of a 21-year-old girl with this condition showed that after struggling with antihistamines for years, multiple courses of omalizumab led to significant improvement and quality of life enhancements.
- The findings support omalizumab as a promising treatment option for patients with persistent solar urticaria, but more research is needed to evaluate long-term effects and possible combinations with other medications.
Article Abstract
Background: Solar urticaria represents an uncomfortable form of chronic inducible urticaria. First and second-line treatments are ineffective in some patients, leading to an impairment in their quality of life. Omalizumab represents a safe therapeutic option in case of refractory solar urticaria.
Case Presentation: We update a case of a 21-year-old Caucasian girl affected by solar urticaria from the age of 14. Poor disease control was achieved with standard or high-dose of H-antihistamines. Several omalizumab courses, including a 1-year-long course, were practiced resulting in clinical remission and significant improvement in patient's quality of life.
Conclusion: Our experience confirms the effectiveness and safety of omalizumab for the management of refractory solar urticaria. Future studies are awaited in order to monitor long term effects and chronic doses of this treatment, particularly in patients who need concomitant therapy with antihistamines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480034 | PMC |
| http://dx.doi.org/10.1186/s13052-021-01151-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!